Fritextsökning
Innehållstyper
-
Compact and leak-tight powerhouse
Media-separated solenoid valve VYKA from Festo is virtually leak-free
-
Hjärnan i 3D – efter en videostund med Matrix
Forskare i USA har skapat det största och mest detaljerade kopplingsschemat hittills av en däggdjurshjärna genom att kartlägga celler i hjärnvävnaden hos en mus...
-
Rise and Scantox cease conducting animal testing in Stockholm
Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...
-
FHM ska leda expertlabb för ebola och okända virussjukdomar
Folkhälsomyndigheten har fått ansvar för att driva det europeiska referenslaboratoriet för smittsamma sjukdomar som ebola, marburg och rabies. Uppdraget omfatta...
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...
-
ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin
More than 50 distinguished speakers from leading manufacturing companies.
-
Confidence in childhood vaccines is in decline worldwide
Since the pandemic, confidence in vaccinating children has plummeted. In a new report, UNICEF urges world leaders to act before the situation worsens. In 52 out...
-
Spatial Biology Studies in Lung Tissue using Spectral Microscopy
Spectral imaging with the ZEISS LSM 980 laser scanning confocal enables more complex studies of cell-cell interactions and locations in immunology research.
-
How to optimise your liquid handling results
In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...
-
Bio-Works
-
The Swedish innovation model: “There is a paradox”
It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?
-
Oncozenges tablett mot munsmärta utlicensieras för Gulf-regionen
Oncozenge har ingått ett licensavtal med Dubaibaserade Avernus Pharma om kommersialisering i Gulf-regionen av Bupizenge, en sugtablett under utveckling för beha...
-
Japanese pharma to buy US drugmaker for $2.4 bln
Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.
-
Positiva data för vaccin i pulverform – ”Fungerar lika bra”
En ny studie indikerar att ett nytt influensavaccin, som utvecklas av Abera Bioscience i samarbete med Orexo, fungerar både som sprej och pulver.
-
Wusson Accelerator AB
-
Webinar: Automate your processes
Free ZEISS webinar on January 30th, 2025.
-
From the sea of Åland to a self-test for lithium
Four years ago, a meeting on the sea of Åland resulted in the development of a self-test for lithium levels in the blood. The hopes are that the test will be av...
-
Column: ”Authentic leadership and clear mandates pave the way for more female CEOs”
”I believe that the aspect of having clear mandates and titles on the one hand and women progressing into top positions must be explored further”, Helena Strigå...
-
Metabolon
-
The Swedish Foundation for Strategic Research
-
Enhance your expertise with your measuring software
Discover the training options in our ZEISS Metrology Portal.
-
He is zooming in on topical preparations
According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting ap...
-
Quiet, fast, inexpensive: mass flow controller for life sciences
Whether in portable oxygen system devices or in bioreactors, the new proportional flow control valve VEMD from Festo provides extremely high control dynamics an...
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...